Technical Analysis for CU6 - Clarity Pharmaceuticals Ltd
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 4.300 | 3.86% | 0.160 |
CU6 closed up 3.86 percent on Monday, May 20, 2024, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | 3.86% | |
| New 52 Week High | Strength | 3.86% | |
| Wide Bands | Range Expansion | 3.86% | |
| Gapped Up | Strength | 3.86% | |
| Overbought Stochastic | Strength | 3.86% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 19 hours ago |
| Up 3% | about 21 hours ago |
| Up 2% | about 22 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| New 52 Week High | about 23 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.33 |
| 52 Week Low | 0.675 |
| Average Volume | 933,823 |
| 200-Day Moving Average | 1.924 |
| 50-Day Moving Average | 3.032 |
| 20-Day Moving Average | 3.441 |
| 10-Day Moving Average | 3.938 |
| Average True Range | 0.186 |
| RSI (14) | 78.21 |
| ADX | 47.12 |
| +DI | 46.773 |
| -DI | 8.370 |
| Chandelier Exit (Long, 3 ATRs) | 3.772 |
| Chandelier Exit (Short, 3 ATRs) | 3.058 |
| Upper Bollinger Bands | 4.650 |
| Lower Bollinger Band | 2.232 |
| Percent B (%b) | 0.86 |
| BandWidth | 70.270 |
| MACD Line | 0.359 |
| MACD Signal Line | 0.297 |
| MACD Histogram | 0.0622 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.615 | ||||
| Resistance 3 (R3) | 4.590 | 4.460 | 4.563 | ||
| Resistance 2 (R2) | 4.460 | 4.380 | 4.473 | 4.545 | |
| Resistance 1 (R1) | 4.380 | 4.330 | 4.420 | 4.405 | 4.527 |
| Pivot Point | 4.250 | 4.250 | 4.270 | 4.263 | 4.250 |
| Support 1 (S1) | 4.170 | 4.170 | 4.210 | 4.195 | 4.073 |
| Support 2 (S2) | 4.040 | 4.120 | 4.053 | 4.055 | |
| Support 3 (S3) | 3.960 | 4.040 | 4.038 | ||
| Support 4 (S4) | 3.985 |
